PTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says

MT Newswires Live

08/08

PTC Therapeutics (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, Morgan Stanley said in a Friday note.

Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.

The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.

On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.

Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.

Shares of PTC Therapeutics were down 7% in recent trading.

Price: 46.85, Change: -3.51, Percent Change: -6.97

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2558752035"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558752035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558752035?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 23:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558752035","market":"sh","top_or_hot":-1,"title":"PTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, <a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> said in a Friday note.</p><p>Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.</p><p>The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.</p><p>On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.</p><p>Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.</p><p>Shares of PTC Therapeutics were down 7% in recent trading.</p><p>Price: 46.85, Change: -3.51, Percent Change: -6.97</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-08-08 23:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, <a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> said in a Friday note.</p><p>Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.</p><p>The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.</p><p>On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.</p><p>Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.</p><p>Shares of PTC Therapeutics were down 7% in recent trading.</p><p>Price: 46.85, Change: -3.51, Percent Change: -6.97</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTC","symbol_name":"PTC Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2558752035","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558752035","pubTimestamp":1754667814,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PTC Therapeutics  Q2 net product revenue and royalties came in modestly ahead of expectations, Morgan Stanley said in a Friday note.Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.Shares of PTC Therapeutics were down 7% in recent trading.Price: 46.85, Change: -3.51, Percent Change: -6.97","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PTC":"PTC Inc.","PTCT":"PTC Therapeutics Inc."},"translate_title":"摩根士丹利表示，PTC Therapeutics第二季度收入小幅增长，Sefience前景成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTC":1,"PTCT":1},"content_text":"PTC Therapeutics (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, Morgan Stanley said in a Friday note.Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.Shares of PTC Therapeutics were down 7% in recent trading.Price: 46.85, Change: -3.51, Percent Change: -6.97","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}